Intravenous Esketamine

Approved

UUniversity of Sao Paulo

Intravenous Esketamine is one of 32 therapeutic programs targeting Suicide. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

SuicideRecruiting

SuicideApproved

Recruiting

Competition

Competitive Landscape

40 competitors in Suicide

#DrugCompanyPhaseTrials

Ketalar

AAultman Health Foundation

Approved

6 2

Estrace

Spravato

2 4

Paxil

SSebela Pharmaceuticals Development LLC

Approved

1 5

Lexapro

AbbVie

Phase 3

1 6

Celexa

AbbVie

Phase 3

1 7

Micronized Progesterone

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Approved

1 8

Wellbutrin

GGlaxo Dba Glaxosmithkline

Phase 3

2 9

Suboxone

IIndivior Inc.

Phase 3

1 10

Effexor

WWyeth-Lederle Vaccines

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

ApprovedRecruiting

Suicide

NCT07120477

Clinical

Trials by Indication[1]

Suicide1 trial

Esketamine Versus Crisis Response Planning Versus Optimized Treatment as Usual for Suicide Prevention: A Pragmatic Controlled Trial in Two Brazilian Cities

Recruiting·UUniversity of Sao Paulo·Approved·NCT07120477·468 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intravenous Esketamine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Intravenous Esketamine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Sao Paulo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Approved[1]
Company: UUniversity of Sao Paulo

Intravenous Esketamine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Suicide1 trial

References

Drug Info

Quick Facts

Related News